Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System

M. van der Burg, T. Kalina, M. Perez-Andres, M. Vlkova, E. Lopez-Granados, E. Blanco, C. Bonroy, AE. Sousa, AK. Kienzler, M. Wentink, E. Mejstríková, V. Šinkorova, J. Stuchly, MC. van Zelm, A. Orfao, JJM. van Dongen,

. 2019 ; 10 (-) : 246. [pub] 20190304

Language English Country Switzerland

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20022846

In the rapidly evolving field of primary immunodeficiencies (PID), the EuroFlow consortium decided to develop a PID orientation and screening tube that facilitates fast, standardized, and validated immunophenotypic diagnosis of lymphoid PID, and allows full exchange of data between centers. Our aim was to develop a tool that would be universal for all lymphoid PIDs and offer high sensitivity to identify a lymphoid PID (without a need for specificity to diagnose particular PID) and to guide and prioritize further diagnostic modalities and clinical management. The tube composition has been defined in a stepwise manner through several cycles of design-testing-evaluation-redesign in a multicenter setting. Equally important appeared to be the standardized pre-analytical procedures (sample preparation and instrument setup), analytical procedures (immunostaining and data acquisition), the software analysis (a multidimensional view based on a reference database in Infinicyt software), and data interpretation. This standardized EuroFlow concept has been tested on 250 healthy controls and 99 PID patients with defined genetic defects. In addition, an application of new EuroFlow software tools with multidimensional pattern recognition was designed with inclusion of maturation pathways in multidimensional patterns (APS plots). The major advantage of the EuroFlow approach is that data can be fully exchanged between different laboratories in any country of the world, which is especially of interest for the PID field, with generally low numbers of cases per center.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022846
003      
CZ-PrNML
005      
20201214124854.0
007      
ta
008      
201125s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2019.00246 $2 doi
035    __
$a (PubMed)30886612
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a van der Burg, Mirjam $u Department of Immunology, Erasmus MC, Rotterdam, Netherlands. Department of Pediatrics, Laboratory for Immunology, Leiden University Medical Center, Leiden, Netherlands.
245    14
$a The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System / $c M. van der Burg, T. Kalina, M. Perez-Andres, M. Vlkova, E. Lopez-Granados, E. Blanco, C. Bonroy, AE. Sousa, AK. Kienzler, M. Wentink, E. Mejstríková, V. Šinkorova, J. Stuchly, MC. van Zelm, A. Orfao, JJM. van Dongen,
520    9_
$a In the rapidly evolving field of primary immunodeficiencies (PID), the EuroFlow consortium decided to develop a PID orientation and screening tube that facilitates fast, standardized, and validated immunophenotypic diagnosis of lymphoid PID, and allows full exchange of data between centers. Our aim was to develop a tool that would be universal for all lymphoid PIDs and offer high sensitivity to identify a lymphoid PID (without a need for specificity to diagnose particular PID) and to guide and prioritize further diagnostic modalities and clinical management. The tube composition has been defined in a stepwise manner through several cycles of design-testing-evaluation-redesign in a multicenter setting. Equally important appeared to be the standardized pre-analytical procedures (sample preparation and instrument setup), analytical procedures (immunostaining and data acquisition), the software analysis (a multidimensional view based on a reference database in Infinicyt software), and data interpretation. This standardized EuroFlow concept has been tested on 250 healthy controls and 99 PID patients with defined genetic defects. In addition, an application of new EuroFlow software tools with multidimensional pattern recognition was designed with inclusion of maturation pathways in multidimensional patterns (APS plots). The major advantage of the EuroFlow approach is that data can be fully exchanged between different laboratories in any country of the world, which is especially of interest for the PID field, with generally low numbers of cases per center.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $x metody $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a imunitní systém $x patologie $7 D007107
650    _2
$a imunofenotypizace $x metody $7 D016130
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a primární imunodeficience $x diagnóza $7 D000081207
650    _2
$a referenční standardy $7 D012015
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kalina, Tomas $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia.
700    1_
$a Perez-Andres, Martin $u Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
700    1_
$a Vlkova, Marcela $u Institute of Clinical Immunology and Allergology, St Anne's University Hospital, Brno, Czechia.
700    1_
$a Lopez-Granados, Eduardo $u Immunology, Universitario La Paz, Madrid, Spain.
700    1_
$a Blanco, Elena $u Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
700    1_
$a Bonroy, Carolien $u Laboratory for Clinical Biology and Hematology, University Hospital Ghent, Ghent, Belgium.
700    1_
$a Sousa, Ana E $u Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.
700    1_
$a Kienzler, Anne-Kathrin $u BRC-Translational Immunology Lab, University of Oxford, Oxford, United Kingdom.
700    1_
$a Wentink, Marjolein $u Department of Immunology, Erasmus MC, Rotterdam, Netherlands.
700    1_
$a Mejstríková, Ester $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia.
700    1_
$a Šinkorova, Vendula $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia.
700    1_
$a Stuchly, Jan $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia.
700    1_
$a van Zelm, Menno C $u Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
700    1_
$a Orfao, Alberto $u Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), University of Salamanca (USAL), Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
700    1_
$a van Dongen, Jacques J M $u Department of Immunology, Erasmus MC, Rotterdam, Netherlands. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 10, č. - (2019), s. 246
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30886612 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124853 $b ABA008
999    __
$a ok $b bmc $g 1595165 $s 1113522
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 246 $e 20190304 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Logged in users only

Archiving options